WEDNESDAY, May 15 (HealthDay News) -- The U.S. Food and Drug
Administration has approved new, lower-dose labeling for the
popular sleep drug Ambien (zolpidem) in an effort to cut down on
daytime drowsiness that could be a hazard while performing certain
tasks such as driving.
The move follows the FDA's request to manufacturers in January
that drugs containing zolpidem carry instructions that lower the
recommended dose and provide more safety information to
"FDA has approved these changes because of the known risk of next-morning impairment with these drugs," the agency said in a statement released Tuesday on its website.
Sleep medications containing zolpidem include Ambien, Ambien CR,
Edluar and Zolpimist, as well as generic versions of Ambien and
"The purpose of the lowering is to help decrease the risk of next-morning impairment of activities that require alertness," Dr. Ellis Unger, director of the Office of Drug Evaluation I at the FDA's Center for Drug Evaluation and Research, said at the time of the agency's request to manufacturers. "We're particularly concerned about driving. A large fraction of the population drives and driving is an inherently dangerous activity."
Lowering the nighttime dose means there will be less residual
drug in the blood by the time the person wakes up. Extended-release
forms of the drugs tend to stay in the body longer, the FDA
The FDA has told manufacturers that recommended doses for women
should be cut in half, from 10 milligrams to 5 milligrams for
immediate-release products (Ambien, Edluar and Zolpimist) and from
12.5 mg to 6.25 mg for extended-release products (Ambien CR).
For men, the agency has asked manufacturers to change the
labeling to recommend that doctors and other health-care
professionals consider prescribing lower doses, meaning 5 mg for
immediate-release products and 6.25 mg for extended-release
In explaining the different recommendations for men and women,
Unger said that "women appear to be more susceptible to risk for
next-morning impairment because they eliminate zolpidem from their
bodies more slowly."
It's not clear why women eliminate the substance from their
bodies more slowly than men.
Although there have been reports of adverse events, including
motor vehicle accidents possibly related to zolpidem, the link has
not and probably cannot be definitely established, Unger said.
The changes were spurred by new driving-simulation studies
showing that currently prescribed levels of drugs containing
zolpidem may be high enough to impair alertness the next day, he
The FDA will be requiring driving-simulation studies for new
sleep medications, and it is assessing other insomnia medications
on the market. Eventually, Unger said, "we want driving data on all
Unger emphasized that next-day impairment is not limited to
medications containing zolpidem but to all sleep medications.
"For all sleep medications, doctors should prescribe and patients should take the lowest dose," he said.
People taking any kind of sleep medication should not change
their dose without first talking to their health-care professional,
Visit the U.S. Food and Drug Administration for more about
next-morning impairment from sleep aids.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.